Sotera Health Analyst Ratings
Sotera Health Analyst Ratings
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $18.00 to $22.00. The current price Sotera Health (SHC) is trading at is $17.64, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 24.72% | RBC Capital | $18 → $22 | Maintains | Outperform |
| 08/04/2023 | 30.39% | Keybanc | $24 → $23 | Maintains | Overweight |
| 06/26/2023 | 36.05% | Keybanc | → $24 | Upgrades | Sector Weight → Overweight |
| 06/22/2023 | — | Keybanc | Maintains | Sector Weight | |
| 05/04/2023 | 2.04% | RBC Capital | $19 → $18 | Maintains | Outperform |
| 05/04/2023 | 13.38% | Barclays | $21 → $20 | Maintains | Overweight |
| 04/04/2023 | 19.05% | Barclays | $22 → $21 | Maintains | Overweight |
| 03/01/2023 | 7.71% | RBC Capital | $8 → $19 | Maintains | Outperform |
| 01/23/2023 | 2.04% | JP Morgan | $6 → $18 | Upgrades | Underweight → Neutral |
| 01/11/2023 | 24.72% | Barclays | $6 → $22 | Upgrades | Underweight → Overweight |
| 01/11/2023 | 41.72% | Wolfe Research | → $25 | Upgrades | Peer Perform → Outperform |
| 11/23/2022 | -54.65% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/16/2022 | -65.99% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/15/2022 | -65.99% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/03/2022 | -65.99% | JP Morgan | $9 → $6 | Maintains | Underweight |
| 11/03/2022 | -54.65% | RBC Capital | $25 → $8 | Maintains | Outperform |
| 10/06/2022 | -54.65% | Barclays | $22 → $8 | Maintains | Equal-Weight |
| 10/05/2022 | -48.98% | Citigroup | → $9 | Downgrades | Buy → Neutral |
| 09/26/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 09/21/2022 | -48.98% | JP Morgan | $26 → $9 | Downgrades | Overweight → Underweight |
| 09/20/2022 | -48.98% | Goldman Sachs | $23 → $9 | Downgrades | Buy → Neutral |
| 07/13/2022 | 24.72% | Barclays | $24 → $22 | Maintains | Equal-Weight |
| 06/09/2022 | 47.39% | Wolfe Research | → $26 | Downgrades | Outperform → Peer Perform |
| 04/06/2022 | 47.39% | Wolfe Research | → $26 | Initiates Coverage On | → Outperform |
| 03/21/2022 | 53.06% | Goldman Sachs | $31 → $27 | Maintains | Buy |
| 03/03/2022 | 24.72% | Jefferies | $34 → $22 | Downgrades | Buy → Hold |
| 03/02/2022 | 58.73% | Credit Suisse | $31 → $28 | Maintains | Outperform |
| 03/02/2022 | 36.05% | Barclays | → $24 | Downgrades | Overweight → Equal-Weight |
| 03/02/2022 | 70.07% | Keybanc | $33 → $30 | Maintains | Overweight |
| 08/13/2021 | 81.41% | Barclays | $30 → $32 | Maintains | Overweight |
| 07/13/2021 | 70.07% | Barclays | $29 → $30 | Maintains | Overweight |
| 03/10/2021 | 87.07% | Keybanc | $31 → $33 | Maintains | Overweight |
| 03/03/2021 | 98.41% | Barclays | → $35 | Initiates Coverage On | → Overweight |
| 01/14/2021 | 75.74% | Baird | → $31 | Initiates Coverage On | → Outperform |
| 12/15/2020 | 75.74% | Keybanc | → $31 | Initiates Coverage On | → Overweight |
| 12/15/2020 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 12/15/2020 | 92.74% | Goldman Sachs | → $34 | Initiates Coverage On | → Buy |
| 12/15/2020 | 89.91% | Jefferies | → $33.5 | Initiates Coverage On | → Buy |
| 12/15/2020 | 75.74% | RBC Capital | → $31 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 24.72% | 加拿大皇家银行资本 | $18→$22 | 维护 | 跑赢大盘 |
| 08/04/2023 | 30.39% | KeyBanc | $24→$23 | 维护 | 超重 |
| 2023/06/26 | 36.05% | KeyBanc | →$24 | 升级 | 行业权重→超配 |
| 2023/06/22 | - | KeyBanc | 维护 | 地段权重 | |
| 05/04/2023 | 2.04% | 加拿大皇家银行资本 | $19→$18 | 维护 | 跑赢大盘 |
| 05/04/2023 | 13.38% | 巴克莱 | $21→$20 | 维护 | 超重 |
| 04/04/2023 | 19.05% | 巴克莱 | $22→$21 | 维护 | 超重 |
| 03/01/2023 | 7.71% | 加拿大皇家银行资本 | $8→$19 | 维护 | 跑赢大盘 |
| 2023年1月23日 | 2.04% | 摩根大通 | $6→$18 | 升级 | 减重→中性 |
| 2023年1月11日 | 24.72% | 巴克莱 | $6→$22 | 升级 | 减持→超重 |
| 2023年1月11日 | 41.72% | 沃尔夫研究 | →$25 | 升级 | 同业表现优于→ |
| 2022年11月23日 | -54.65% | 高盛 | $9→$8 | 维护 | 中性 |
| 2022年11月16日 | -65.99% | 巴克莱 | $7→$6 | 评级下调 | 等重→减码 |
| 2022年11月15日 | -65.99% | 巴克莱 | $7→$6 | 评级下调 | 等重→减码 |
| 11/03/2022 | -65.99% | 摩根大通 | $9→$6 | 维护 | 体重不足 |
| 11/03/2022 | -54.65% | 加拿大皇家银行资本 | $25→$8 | 维护 | 跑赢大盘 |
| 10/06/2022 | -54.65% | 巴克莱 | $22→$8 | 维护 | 等重 |
| 10/05/2022 | -48.98% | 花旗集团 | →$9 | 评级下调 | 购买→中性 |
| 09/26/2022 | - | KeyBanc | 评级下调 | 增持→板块权重 | |
| 2022/09/21 | -48.98% | 摩根大通 | $26→$9 | 评级下调 | 增持→减持 |
| 09/20/2022 | -48.98% | 高盛 | $23→$9 | 评级下调 | 购买→中性 |
| 07/13/2022 | 24.72% | 巴克莱 | $24→$22 | 维护 | 等重 |
| 06/09/2022 | 47.39% | 沃尔夫研究 | →$26 | 评级下调 | 超越→同行的表现 |
| 04/06/2022 | 47.39% | 沃尔夫研究 | →$26 | 开始承保 | →跑赢大盘 |
| 03/21/2022 | 53.06% | 高盛 | $31→$27 | 维护 | 买 |
| 03/03/2022 | 24.72% | 杰富瑞 | $34→$22 | 评级下调 | 购买→Hold |
| 03/02/2022 | 58.73% | 瑞士信贷 | $31→$28 | 维护 | 跑赢大盘 |
| 03/02/2022 | 36.05% | 巴克莱 | →$24 | 评级下调 | 超重→等重 |
| 03/02/2022 | 70.07% | KeyBanc | $33→$30 | 维护 | 超重 |
| 2021/08/13 | 81.41% | 巴克莱 | $30→$32 | 维护 | 超重 |
| 07/13/2021 | 70.07% | 巴克莱 | $29→$30 | 维护 | 超重 |
| 03/10/2021 | 87.07% | KeyBanc | $31→$33 | 维护 | 超重 |
| 03/03/2021 | 98.41% | 巴克莱 | →$35 | 开始承保 | →超重 |
| 2021/01/14 | 75.74% | 贝尔德 | →$31 | 开始承保 | →跑赢大盘 |
| 12/15/2020 | 75.74% | KeyBanc | →$31 | 开始承保 | →超重 |
| 12/15/2020 | - | 瑞士信贷 | 开始承保 | →跑赢大盘 | |
| 12/15/2020 | 92.74% | 高盛 | →$34 | 开始承保 | →购买 |
| 12/15/2020 | 89.91% | 杰富瑞 | →$33.5 | 开始承保 | →购买 |
| 12/15/2020 | 75.74% | 加拿大皇家银行资本 | →$31 | 开始承保 | →跑赢大盘 |
What is the target price for Sotera Health (SHC)?
Sotera Health(SHC)的目标价格是多少？
The latest price target for Sotera Health (NASDAQ: SHC) was reported by RBC Capital on August 4, 2023. The analyst firm set a price target for $22.00 expecting SHC to rise to within 12 months (a possible 24.72% upside). 21 analyst firms have reported ratings in the last year.
加拿大皇家银行资本于2023年8月4日报道了Sotera Health(纳斯达克：SHC)的最新目标价。这家分析公司将目标价定为22.00美元，预计SHC将在12个月内上涨(可能上涨24.72%)。去年有21家分析公司公布了评级。
What is the most recent analyst rating for Sotera Health (SHC)?
索特拉健康公司(Sotera Health)最近的分析师评级是多少？
The latest analyst rating for Sotera Health (NASDAQ: SHC) was provided by RBC Capital, and Sotera Health maintained their outperform rating.
加拿大皇家银行资本提供了对Sotera Health(纳斯达克：SHC)的最新分析师评级，Sotera Health维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Sotera Health(SHC)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Sotera Health的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sotera Health的上一次评级是在2023年8月4日提交的，所以你应该预计下一次评级将在2024年8月4日左右提供。
Is the Analyst Rating Sotera Health (SHC) correct?
分析师对Sotera Health(SHC)的评级正确吗？
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $18.00 to $22.00. The current price Sotera Health (SHC) is trading at is $17.64, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Sotera Health(SHC)评级维持不变，目标价在18.00美元至22.00美元之间。Sotera Health目前的股价为17.64美元，超出了分析师的预测范围。